At a glance
- Originator Sanofi Winthrop
- Class Antineoplastics
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
- 20 Aug 1998 Profile reviewed
- 02 May 1996 Preclinical development for Cancer in USA (Unknown route)